Protalix BioTherapeutics
PLX
34 hedge funds and large institutions have $7.6M invested in Protalix BioTherapeutics in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
21% more funds holding
Funds holding: 28 → 34 (+6)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
16% more call options, than puts
Call options by funds: $202K | Put options by funds: $174K
0.03% more ownership
Funds ownership: 0.68% → 0.72% (+0.03%)
34% less capital invested
Capital invested by funds: $11.5M → $7.6M (-$3.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$663K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$646K |
| 3 |
Renaissance Technologies
New York
|
+$350K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$347K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$305K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$2.14M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$186K |
| 3 |
Jane Street
New York
|
-$111K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$104K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$98.5K |
PLX Hedge Fund Activity: Q2 2017 in Review
34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2017, worth a combined $7.6M — down 34% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PLX positions and 5 closed out — a net gain of 6 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $663K. The largest seller was Ion Asset Management, exiting entirely with an estimated $2.14M sold.
- 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2017, up from 28 in Q1 2017.
- Funds reported $7.6M of Protalix BioTherapeutics stock for Q2 2017, down 34% quarter-over-quarter.
- 11 funds opened new Protalix BioTherapeutics positions in Q2 2017 and 5 closed out, a net change of +6 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $663K added.
- The largest Protalix BioTherapeutics seller in Q2 2017 was Ion Asset Management, an estimated $2.14M sold.
Based on aggregated 13F filings for Q2 2017.